Taiwan’s Medigen Vaccine Biologics expressed that it was seeking emergency use authorization, or EUA, from the local government for its COVID-19 vaccine which has already finished phase 2 trials.
Medigen’s recombinant protein vaccine was developed in partnership with the National Institutes of Health in the United States.
Medigen’s chief executive, Charles Chen, said that the phase two results were successful and that they would be submitting the EUA to the Taiwanese food and drug administration soon.
There were reportedly 4,000 participants Medigen’s second phase clinical trial and received two shots without adverse side effects.
“Safety is very important, and our vaccine is very safe,” reassured Chen.
Chen added that it will produce 100 million doses for export to countries with friendly ties.
Medigen said that it would apply to the European Medicines Agency and other international health authorities to start phase 3 clinical trials in order to gain international credibility.
Medigen’s breakthrough came amid an ongoing outbreak in Taiwan along with vaccine shortages.
Only 3 percent of Taiwan’s 23.5 million total population have received at least one shot while most of the local vaccine supplies only came from donations.
© Fourth Estate
® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.